Stockreport

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigat [Read more]